Supramolecular chitosan-epigallocatechin gallate-ionic salt and preparation method and application thereof

By forming hydrogen bonds or intermolecular forces between chitosan substances and epicatechol ester, combining additives to form supramolecular chitosan-episocatechol ester-ionic salts, the solution is solved The problem of poor stability in the prior art is improved, the bioavailability and transdermal absorption effect are enhanced, and biological activity is enhanced.

CN119039482APending Publication Date: 2024-11-29BEIJING UNDERPROVED MEDICAL TECH CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410996590.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

In the prior art, when chitosan substances and epithelial catechol esters are combined through physical mixing or compounding, the transdermal absorption effect and stability are poor.

Method used

By forming hydrogen bonds or intermolecular forces between chitosan substances and epicatechol esters, combined with additives such as malic acid, citric acid, etc., supramolecular chitosan-episocatechol esters are formed Acid ester-ionic salt is prepared by ionization salt reaction, evaporation treatment and drying treatment to improve its stability and bioavailability.

Benefits of technology

It significantly improves the bioavailability and transdermal absorption effect of chitosan substances and epithelial catechol esters, enhances its antioxidant, anti-aging, antibacterial and soothing skin care bioactivity, and the preparation method is gentle, The steps are simple and the product is of high purity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039482A_ABST
    Figure CN119039482A_ABST
Patent Text Reader

Abstract

The invention discloses supramolecular chitosan-epigallocatechin gallate-ionic salt as well as a preparation method and application thereof, the supramolecular chitosan-epigallocatechin gallate-ionic salt comprises three main bodies, namely a chitosan substance, epigallocatechin gallate and an additive, every two main bodies are connected through hydrogen bonds or intermolecular acting force. The supramolecular chitosan-epigallocatechin gallate-ionic salt has good biocompatibility and mildness, the bioavailability of chitosan substances and epigallocatechin gallate is improved, the transdermal absorption effect and stability of the chitosan substances and epigallocatechin gallate are greatly improved, and the supramolecular chitosan-epigallocatechin gallate-ionic salt completely retains the molecular skeleton of supramolecules, so that the preparation method is simple and easy to implement. The biological activity and the effect of the supramolecular chitosan-epigallocatechin gallate-ionic salt are improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of supramolecular technology, in particular to a supramolecular chitosan-epigallocatechin gallate-ion salt and a preparation method and application thereof. Background Art

[0002] Chitosan substances have good moisture absorption, moisturizing, conditioning, antibacterial and other functions. They can be used in skin care products. They are currently used in advanced cosmeceuticals. They can be used after pulsed light, radio frequency, fractional matrix, fruit acid and other medical cosmetic procedures to play the role of natural antibiotics to resist sensitivity and inflammation. They can also be used to treat skin inflammation such as acne or pimples, quickly repair basal thermal damage, quickly heal wounds, and repair epidermal barriers. Epigallocatechin gallate is a natural whitening ingredient with multiple functions, including inhibiting the production of melanin, anti-oxidation and anti-inflammatory effects.

[0003] Physically mixed or compounded chitosan substances, epigallocatechin gallate and ligands cannot form intermolecular forces with each other, resulting in poor transdermal absorption effect and stability.

[0004] Therefore, the prior art still needs to be improved and developed. Summary of the invention

[0005] In view of the above-mentioned deficiencies in the prior art, the present invention provides a supramolecular chitosan-epigallocatechin gallate-ionic salt and a preparation method and application thereof to solve the problem of poor stability of chitosan substances combined with epigallocatechin gallate and ligands by physical mixing or compounding.

[0006] The technical solution adopted by the present invention to solve the above technical problems is as follows:

[0007] In a first aspect of the present invention, a supramolecular chitosan-epigallocatechin gallate-ionic salt is provided, wherein the supramolecular chitosan-epigallocatechin gallate-ionic salt comprises three main bodies, namely, chitosan-like substance, epigallocatechin gallate and additive, and every two main bodies are connected by hydrogen bonds or intermolecular forces.

[0008] Preferably, the mass ratio of the chitosan substance, epigallocatechin gallate and the additive is (1-10):(1-10):(1-10).

[0009] Preferably, the mass ratio of the chitosan substance, epigallocatechin gallate and the additive is 1:1:5.

[0010] Preferably, the chitosan-based substance is selected from one or more of chitosan, carboxymethyl chitosan, and chitosan derivatives.

[0011] Preferably, the additive is selected from one or more of malic acid, citric acid, lactic acid, tartaric acid, glycolic acid, mandelic acid, azelaic acid, salicylic acid, hydroxypropyl cyclodextrin, and trehalose.

[0012] The second aspect of the present invention provides a method for preparing the supramolecular chitosan-epigallocatechin gallate-ionic salt, the preparation method comprising the following steps:

[0013] The chitosan material, epigallocatechin gallate and additives are dispersed in a solvent, and an ionization salt-forming reaction is carried out, and then the supramolecular chitosan-epigallocatechin gallate-ion salt is obtained after evaporation treatment and drying treatment.

[0014] Preferably, the time for the ionization salt-forming reaction is 1 h to 24 h.

[0015] Preferably, the temperature of the evaporation treatment is 30°C-100°C, and the time is 1h-4h; the temperature of the drying treatment is 30°C-100°C, and the time is 4h-48h.

[0016] Preferably, the solvent is selected from one or more of ethanol, water, methanol, isopropanol, acetone, propylene glycol, butylene glycol, and pentanediol.

[0017] In a third aspect of the present invention, the supramolecular chitosan-epigallocatechin gallate-ionic salt is used to prepare antioxidant, anti-aging, antibacterial, oil-controlling, anti-inflammatory, soothing skin care products or to prepare carriers for drug delivery.

[0018] Beneficial effects:

[0019] The invention discloses a supramolecular chitosan-epigallocatechin gallate-ion salt and a preparation method and application thereof. The supramolecular chitosan-epigallocatechin gallate-ion salt comprises three main bodies, namely, chitosan substances, epigallocatechin gallate and additives. Every two main bodies are connected by hydrogen bonds or intermolecular forces. The supramolecular chitosan-epigallocatechin gallate-ion salt has good biocompatibility and mildness, improves the bioavailability of chitosan substances and epigallocatechin gallate, greatly improves the transdermal absorption effect and stability thereof, and the supramolecular chitosan-epigallocatechin gallate-ion salt completely retains the molecular skeleton of the supramolecular, so that the biological activity and efficacy of the supramolecular chitosan-epigallocatechin gallate-ion salt are improved.

[0020] In addition, the preparation method of the present invention has mild reaction conditions, simple synthesis steps, convenient post-treatment, high purity and high yield of the obtained product, and can meet general research requirements. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1This is the H-NMR spectrum of the supramolecular chitosan-epigallocatechin gallate-malic acid prepared in Example 1 of the present invention.

[0022] Figure 2 This is the H-NMR spectrum of the supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose prepared in Example 2 of the present invention.

[0023] Figure 3 This is a two-dimensional H-NMR spectrum of the supramolecular chitosan-epigallocatechin gallate-malic acid prepared in Example 1 of the present invention.

[0024] Figure 4 This is a two-dimensional H-NMR spectrum of the supramolecular chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose prepared in Example 2 of the present invention.

[0025] Figure 5 Transmission electron micrographs of the supramolecular chitosan-epigallocatechin gallate-malic acid prepared in Example 1 of the present invention and the supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose prepared in Example 2.

[0026] Figure 6 This is a graph showing the transdermal efficiency of the supramolecular chitosan-epigallocatechin gallate-malic acid prepared in Example 1 of the present invention and the supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose prepared in Example 2.

[0027] Figure 7 This is a graph showing the keratinocyte viability of the supramolecular chitosan-epigallocatechin gallate-malic acid prepared in Example 1 of the present invention and the supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose prepared in Example 2.

[0028] Figure 8 This is a graph showing the DPPH radical scavenging rates of the supramolecular chitosan-epigallocatechin gallate-malic acid prepared in Example 1 of the present invention and the supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose prepared in Example 2.

[0029] Fig. 9 This is a graph showing the inhibition rate of supramolecular chitosan-epigallocatechin gallate-malic acid prepared in Example 1 of the present invention and supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose prepared in Example 2 on 5-α reductase.

[0030] Fig.10This is a graph showing the relative contents of the inflammatory factors interleukin-1α (IL-1α) and interleukin-8 (IL-8) in the supramolecular chitosan-epigallocatechin gallate-malic acid prepared in Example 1 of the present invention and the supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose prepared in Example 2. DETAILED DESCRIPTION

[0031] The present invention provides a supramolecular chitosan-epigallocatechin gallate-ion salt and its preparation method and application. In order to make the purpose, technical scheme and effect of the present invention clearer and more specific, the present invention is further described in detail below. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0032] The embodiment of the present invention provides a supramolecular chitosan-epigallocatechin gallate-ionic salt, which comprises three main bodies, namely, chitosan-like substance, epigallocatechin gallate and additives, and every two main bodies are connected by hydrogen bonds or intermolecular forces.

[0033] The supramolecular chitosan-epigallocatechin gallate-ionic salt provided in the embodiment of the present invention has good stability. This is because the supramolecular technology can form hydrogen bonds or intermolecular forces between epigallocatechin gallate and chitosan substances. The existence of such forces can reduce the discoloration and instability of epigallocatechin gallate, thereby improving its stability.

[0034] In some embodiments, the mass ratio of the chitosan substance, epigallocatechin gallate and the additive is (1-10):(1-10):(1-10). The mass ratio of the chitosan substance, epigallocatechin gallate and the additive can be 1:(1-10):1, 1:(1-10):2, 1:(1-10):3, 1:(1-10):4, 1:(1-10):5, 1:(1-10):6, 1:(1-10):7, 1:(1-10):8, 1:(1-10):9, 1:(1-10):10, (1-10):2:1, (1-10):3:1, (1-10):4 :1, (1-10):5:1, (1-10):6:1, (1-10):7:1, (1-10):8:1, (1-10):9:1, (1-10):10:1, 2:1:(1-10), 3:1:(1-10), 4:1:(1-10), 5:1:(1-10), 6:1:(1-10), 7:1:(1-10), 8:1:(1-10), 9:1:(1-10), 10:1:(1-10). This is mainly because epigallocatechin gallate at this mass ratio can not only maintain its good antioxidant activity, but also synergistically increase its stability and bioavailability.

[0035] In some preferred embodiments, the mass ratio of the chitosan substance, epigallocatechin gallate and the additive is 1:1:5.

[0036] In some embodiments, the chitosan-based substance is selected from one or more of chitosan, carboxymethyl chitosan, and chitosan derivatives.

[0037] In some embodiments, the additive is selected from one or more of malic acid, citric acid, lactic acid, tartaric acid, glycolic acid, mandelic acid, azelaic acid, salicylic acid, hydroxypropyl cyclodextrin, and trehalose.

[0038] As a food additive, malic acid can effectively inhibit the formation of melanin and has a certain whitening and freckle removal effect. Citric acid as an acidulant can increase the stability of emulsions and prevent oxidation. Lactic acid is an important edible organic acid that can be absorbed by the human body and is a good acidulant. Tartaric acid has antioxidant properties and can help remove dead skin cells from the surface of the skin naturally. It improves the texture and appearance of the skin, and it allows other products to penetrate the skin more easily. Glycolic acid is a fruit acid derived from sugar cane. It is the fruit acid with the smallest molecular weight and the easiest transdermal absorption. It is widely used in acne-removing skin care products. Its mechanism of action is to reduce the adhesion of keratinocytes by interfering with the binding force of the cell surface, accelerate the shedding and renewal of epidermal cells, and has a certain effect in the treatment of acne. Since melanin is deposited in the stratum corneum, glycolic acid can accelerate the detachment of the stratum corneum, thereby accelerating the metabolism of melanin and playing a whitening role. The main effect of mandelic acid on the skin is to remove scaly keratin. For the outermost stratum corneum, it can reduce the adhesion between keratinocytes and assist the shedding and metabolism of the stratum corneum. As one of the common active ingredients in cosmetics, azelaic acid has multiple effects such as moisturizing, anti-oxidation and antibacterial, which can improve skin texture and prevent skin aging and inflammation. Salicylic acid is fat-soluble and can penetrate deep into the pores to dissolve oil, dredge sebaceous glands, regulate keratin, improve skin photoaging, and has a two-way keratin regulation effect. In addition, salicylic acid can penetrate pores, dissolve aged keratin, dilute pigmentation, enhance the metabolism of skin cells, play a role in skin rejuvenation and whitening, prevent acne scars, dilute acne scars, and prevent ultraviolet damage and photoaging. The effects of hydroxypropyl cyclodextrin on the skin mainly include moisturizing, anti-inflammatory and sedative, anti-allergic, anti-oxidation, and promoting collagen synthesis. It is a safer skin care product. Its main ability in cosmetics lies in its ability to odor, which plays a role in stabilizing the fragrance and enhancing the stability of the product. Trehalose, as a common moisturizer, is widely used in cosmetics and skin care products. Trehalose does not cause obvious harm to the skin and has good moisturizing effect and antioxidant properties.

[0039] Furthermore, the above-mentioned additives can form hydrogen bonds or intermolecular forces with chitosan substances or epigallocatechin gallate. By utilizing hydrogen bonds or intermolecular forces, the dissolution of chitosan substances can be improved on the one hand, and the stability of epigallocatechin gallate can be increased on the other hand.

[0040] The embodiment of the present invention provides a method for preparing the supramolecular chitosan-epigallocatechin gallate-ionic salt, the preparation method comprising the following steps:

[0041] The chitosan material, epigallocatechin gallate and additives are dispersed in a solvent, and an ionization salt-forming reaction is carried out, and then the supramolecular chitosan-epigallocatechin gallate-ion salt is obtained after evaporation treatment and drying treatment.

[0042] In some embodiments, the preparation method comprises the following steps:

[0043] Chitosan-epigallocatechin gallate-ion salt solution is obtained by reacting chitosan-epigallocatechin gallate with additives through ionization and salt formation reaction;

[0044] The chitosan-epigallocatechin gallate-ion salt solution is subjected to a rotary evaporator to remove the solvent to obtain supramolecular chitosan-epigallocatechin gallate-ion salt;

[0045] The supramolecular chitosan-epigallocatechin gallate-ion salt is recrystallized to obtain supramolecular chitosan-epigallocatechin gallate-ion salt with high purity.

[0046] In some embodiments, the chitosan-epigallocatechin gallate-ion salt solution is concentrated to 1 / 5 to 1 / 10 of its volume under vacuum conditions, and then subjected to reduced pressure distillation and recrystallization to obtain pure supramolecular chitosan-epigallocatechin gallate-ion salt.

[0047] In some embodiments, after the chitosan-epigallocatechin gallate-ionic salt solution is subjected to distillation and recrystallization treatment, the method further comprises the steps of filtering and separating the prepared chitosan-epigallocatechin gallate-ionic salt and vacuum drying the chitosan-epigallocatechin gallate-ionic salt in sequence, wherein the drying temperature is 30° C.-100° C. and the drying time is 4 h-48 h, so as to completely remove the remaining water or solvents such as ethanol therein.

[0048] In some embodiments, the time of the ionization salt-forming reaction is 1 h-24 h. The time of the ionization salt-forming reaction can be 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 10 h, 11 h, 12 h, 13 h, 14 h, 15 h, 16 h, 17 h, 18 h, 19 h, 20 h, 21 h, 22 h, 23 h, 24 h.

[0049] This is mainly because a reaction time that is too short will result in incomplete reaction, and a reaction time that is too long will cause epigallocatechin gallate to oxidize and lose its activity.

[0050] In some preferred embodiments, the ionization salt-forming reaction time is 24 hours.

[0051] In some embodiments, the temperature of the evaporation treatment is 30°C-100°C, and the time is 1-4h. The temperature of the evaporation treatment can be 30°C-40°C, 40°C-50°C, 50°C-60°C, 60°C-70°C, 70°C-80°C, 80°C-90°C, 90°C-100°C, and the time can be 1h, 2h, 3h, or 4h.

[0052] In some preferred embodiments, the evaporation treatment is carried out at a temperature of 50° C. and for a time of 1 hour.

[0053] In some embodiments, the drying temperature is 30°C-100°C, and the time is 4h-48h. The drying temperature can be 30°C-40°C, 40°C-50°C, 50°C-60°C, 60°C-70°C, 70°C-80°C, 80°C-90°C, 90°C-100°C, and the time can be 4h-8h, 8h-16h, 16h-20h, 20h-24h, 24h-28h, 28h-32h, 32h-36h, 36h-40h, 40h-44h, 44h-48h.

[0054] In some embodiments, the solvent is selected from one or more of ethanol, water, methanol, isopropanol, acetone, propylene glycol, butylene glycol, and pentanediol, which can improve the recrystallization separation result of the final supramolecular chitosan-epigallocatechin gallate-ion salt.

[0055] The embodiment of the present invention provides an application of supramolecular chitosan-epigallocatechin gallate-ionic salt, wherein the supramolecular chitosan-epigallocatechin gallate-ionic salt is used to prepare antioxidant, anti-aging, antibacterial, oil-controlling, anti-inflammatory, soothing skin care products or to prepare carriers for delivering drugs.

[0056] The embodiment of the present invention also provides an application of supramolecular chitosan-epigallocatechin gallate-ion salt, wherein the supramolecular chitosan-epigallocatechin gallate-ion salt described in the embodiment of the present invention is used as a raw material for the formulation of cosmetics, medicines and life sciences; or, the supramolecular chitosan-epigallocatechin gallate-ion salt described in the embodiment of the present invention is used as a medicinal ingredient for drugs such as transdermal delivery. In other words, the supramolecular chitosan-epigallocatechin gallate-ion salt described in this embodiment can be used as a raw material for the formulation of medicines and cosmetics, and can also be used as a raw material for drugs such as carriers for drug delivery.

[0057] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments, and are only for illustrating the present invention but not limiting the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in the field without creative work are within the scope of protection of the present invention.

[0058] Example 1

[0059] A preparation method of supramolecular chitosan-epigallocatechin gallate-malic acid comprises the following steps:

[0060] Under a nitrogen atmosphere, 1 g of chitosan and 1 g of epigallocatechin gallate were dissolved in 10 mL of ethanol in a reactor, 5 g of malic acid were dissolved in 10 mL of water, and the mixture was added dropwise to the reactor in which chitosan and epigallocatechin gallate were dissolved, and the mixture was heated to 40° C. to perform an ionization salt-forming reaction for 24 hours to obtain a chitosan-epigallocatechin gallate-malic acid solution;

[0061] After the reaction is completed, the supermolecular chitosan-epigallocatechin gallate-malic acid is obtained by evaporation under vacuum conditions, and the supermolecular chitosan-epigallocatechin gallate-malic acid with a purity exceeding 99% is obtained by drying for 48 hours, with a yield of 95.37%.

[0062] The melting point of the supramolecular chitosan-epigallocatechin gallate-malic acid prepared in this example is 203°C.

[0063] Example 2

[0064] A preparation method of supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose comprises the following steps:

[0065] Under a nitrogen atmosphere, 1 g of carboxymethyl chitosan and 1 g of epigallocatechin gallate were dissolved in 10 mL of ethanol in a reactor, and then an aqueous solution containing 1 g of hydroxypropyl cyclodextrin and 1 g of trehalose was added dropwise thereto, and the mixture was heated to 40° C. to perform an ionization salt-forming reaction for 24 hours to obtain a carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose solution;

[0066] After the reaction is completed, the supermolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose is obtained by evaporation under vacuum conditions, and the supermolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose with a purity of more than 95% is obtained by drying for 48 hours, and the yield is 95.58%.

[0067] The melting point of the supramolecular chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose prepared in this example is 352°C.

[0068] like Figure 1 As shown, the H-NMR spectrum data of supramolecular chitosan-epigallocatechin gallate-malic acid prepared in Example 1 of the present invention are: 1H NMR(400MHz,DMSO)δ9.68(s,2H),9.37(s,3H),8.89(m,3H),7.92(m,3H),6.68(s,1H),6.62(dd,1H)6.14(t,6H),5.39(m,3H ),4.99(s,6H);4.81(d,4H);4.53(dd,4H),3.73(m,2H),3.37(s,6H);2.13(s,4H);2.00(dd,5H),1.80(m,2H);1.24(s,4H).

[0069] The NMR carbon spectrum data are: 13 C NMR(400MHz, DMSO)δ175.61(s),171.51(s),165.66(s),156.96(s),156.07(s),145.97(s),139.00(s),132.80(s),129 .07(s),119.71(s),109.10(s),105.91(s),97.81(s),95.68(s),94.44(s),76.14(s),69.29(s),65.45(s),25.28(s).

[0070] like Figure 2 As shown, the H NMR spectrum data of the supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose prepared in Example 2 of the present invention are: 1 H NMR(400MHz,DMSO)δ9.29(s,1H),9.20(s,1H),9.05(s,1H),8.91(s,1H), 8.72(s,1H),8.04(s,1H)6.82(s,2H),6.39(d,2H),5.92(m,2H);5.80(m, 6H),5.71(d,1H),5.36(s,1H),4.92(m,6H),4.87(m,4H),4.57(m,4H),4. 35(t,8H),3.67-2.93(ddd,18H),1.24(s,2H),1.03(s,10H),0.86(s,7H).

[0071] The NMR carbon spectrum data are: 13C NMR(400MHz,DMSO)δ165.87(s),156.91(s),156.01(s),145.90(s),138.96(s),132.73(s),129.11(s),1 19.72(s),109.12(s),105.94(s),102.20(s),101.93(s),100.94(s),97.11(s),95.69(s),94.99(s),93. 46(s),81.96(s),77.86(s),76.45(s),73.28(s),72.82(s),72.69(s),71.97(s),70.53(s),68.21(s),6 5.79(s),65.51(s),60.80(s),60.41(s),20.62(s),20.21(s),20.14(s),20.06(s),19.77(s),19.96(s).

[0072] Depend on Figure 3 It can be seen that there is an interaction force between chitosan, epigallocatechin gallate and malic acid, which indicates that a supramolecular structure is formed between chitosan, epigallocatechin gallate and malic acid.

[0073] Depend on Figure 4 It can be seen that there is an interaction force between carboxymethyl chitosan, epigallocatechin gallate, hydroxypropyl cyclodextrin and trehalose, indicating that a supramolecular structure is formed between carboxymethyl chitosan, epigallocatechin gallate, hydroxypropyl cyclodextrin and trehalose.

[0074] Depend on Figure 5 It can be seen that the particle size of supramolecular chitosan-epigallocatechin gallate-malic acid is about 17.9 nm and is evenly dispersed; the particle size of supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose is about 8.6 nm and is evenly dispersed.

[0075] Depend on Figure 6 It can be seen that the permeability of supramolecular chitosan-epigallocatechin gallate-malic acid is 8.78 times that of epigallocatechin gallate and 2.01 times that of the physical mixed chitosan-epigallocatechin gallate-malic acid; the permeability of supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose is 26.54 times that of epigallocatechin gallate and 4.06 times that of the physical mixed carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose.

[0076] Depend on Figure 7It can be seen that when the mass ratio of supramolecular chitosan-epigallocatechin gallate-malic acid in aqueous solution is 10%, the cell viability of supramolecular chitosan-epigallocatechin gallate-malic acid is higher than 90%, indicating that supramolecular chitosan-epigallocatechin gallate-malic acid has good safety and biocompatibility at this concentration; when the mass ratio is 10%, the cell viability of supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose is higher than 90%, indicating that supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose has good safety and biocompatibility at this concentration.

[0077] Depend on Figure 8 It can be seen that when the concentration of supramolecular chitosan-epigallocatechin gallate-malic acid is 0.5%, the scavenging rate of supramolecular chitosan-epigallocatechin gallate-malic acid on DPPH free radicals is 79.54%, while the scavenging rate of physical mixed chitosan-epigallocatechin gallate-malic acid on DPPH free radicals is 73.92%; when the concentration is 0.5%, the scavenging rate of supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose on DPPH free radicals is 91.23%, while the scavenging rate of physical mixed carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose on DPPH free radicals is 83.67%.

[0078] Depend on Fig. 9 It can be seen that when the concentration of supramolecular chitosan-epigallocatechin gallate-malic acid is 5%, the inhibition rate of supramolecular chitosan-epigallocatechin gallate-malic acid on 5α-reductase is 75.48%, which is better than that of physical mixed chitosan-epigallocatechin gallate-malic acid (the inhibition rate of 5α-reductase is 62.34%); when the concentration is 5%, the inhibition rate of supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose on 5α-reductase is 86.61%, which is better than that of physical mixed carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose (the inhibition rate of 5α-reductase is 74.11%).

[0079] Depend on Fig.10It can be seen that when the concentration of supramolecular carboxymethyl chitosan-epigallocatechin gallate-malic acid is 0.3%, the inhibition rate of supramolecular carboxymethyl chitosan-epigallocatechin gallate-malic acid on IL-1α is 17.29%, which is better than that of physical mixed carboxymethyl chitosan-epigallocatechin gallate-malic acid (the inhibition rate of IL-1α is -1.79%). When the concentration is 0.3%, the inhibition rate of supramolecular carboxymethyl chitosan-epigallocatechin gallate-malic acid on IL-8 is 17.29%. The inhibition rate of supramolecular carboxymethyl chitosan-epigallocatechin gallate-malic acid was 21.34%, which was better than that of physical mixture carboxymethyl chitosan-epigallocatechin gallate-malic acid (the inhibition rate of IL-8 was -7.45%); at a concentration of 0.3%, the inhibition rate of supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose on IL-1α was 19.67%, which was better than that of physical mixture carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose (the inhibition rate of IL-1α was 2.39%). At a concentration of 0.3%, the inhibition rate of supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose on IL-8 was 27.22%, which was better than that of physical mixture carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose (the inhibition rate of IL-8 was -2.79%).

[0080] As shown in Table 1 below, the minimum inhibitory concentration of supramolecular chitosan-epigallocatechin gallate-malic acid is 6%, while the physical mixed chitosan-epigallocatechin gallate-malic acid has no antibacterial effect at 10%; the minimum inhibitory concentration of supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose is 0.5%, while the minimum inhibitory concentration of the physical mixed carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose is 1%.

[0081] Table 1

[0082]

[0083] Therefore, all the above results indicate that supramolecular chitosan-epigallocatechin gallate-malic acid and supramolecular carboxymethyl chitosan-epigallocatechin gallate-hydroxypropyl cyclodextrin-trehalose have good biocompatibility and high bioavailability, and improve the stability of epigallocatechin gallate.

[0084] In summary, the present invention provides a supramolecular chitosan-epigallocatechin gallate-ion salt and its preparation method and application. The present invention uses chitosan or carboxymethyl chitosan and other chitosan-like substances and epigallocatechin gallate as cationic precursors, and uses malic acid, citric acid, lactic acid, tartaric acid, glycolic acid, mandelic acid, azelaic acid, salicylic acid, hydroxypropyl cyclodextrin, trehalose and other additives as anionic precursors, synthesizes supramolecular chitosan-epigallocatechin gallate-ion salt solution through ionization salt-forming reaction, and separates and purifies through concentrated crystallization after the reaction is completed to obtain supramolecular chitosan-epigallocatechin gallate-ion salt. Compared with single epigallocatechin gallate, supramolecular chitosan-epigallocatechin gallate-ion salt improves skin permeability and stability, and simultaneously has the antioxidant and repairing effects and biological activities of supramolecular chitosan-epigallocatechin gallate and a single ligand.

[0085] It should be understood that the application of the present invention is not limited to the above examples. For ordinary technicians in this field, improvements or changes can be made based on the above description. All these improvements and changes should fall within the scope of protection of the claims attached to the present invention.

Claims

1. A supramolecular chitosan-epigallocatechin gallate-ion salt, characterized in that: The supramolecular chitosan-epigallocatechin gallate-ionic salt comprises three main bodies, namely, chitosan-like substances, epigallocatechin gallate and additives, and every two main bodies are connected by hydrogen bonds or intermolecular forces.

2. The supramolecular chitosan-epigallocatechin gallate-ion salt according to claim 1, characterized in that: The mass ratio of the chitosan substance, epigallocatechin gallate and the additive is (1-10):(1-10):(1-10).

3. The supramolecular chitosan-epigallocatechin gallate-ion salt according to claim 1, characterized in that: The mass ratio of the chitosan substance, epigallocatechin gallate and the additive is 1:1:

5.

4. The supramolecular chitosan-epigallocatechin gallate-ion salt according to claim 1, characterized in that: The chitosan-based substance is selected from one or more of chitosan, carboxymethyl chitosan, and chitosan derivatives.

5. The supramolecular chitosan-epigallocatechin gallate-ion salt according to claim 1, characterized in that: The additive is selected from one or more of malic acid, citric acid, lactic acid, tartaric acid, glycolic acid, mandelic acid, azelaic acid, salicylic acid, hydroxypropyl cyclodextrin and trehalose.

6. A method for preparing the supramolecular chitosan-epigallocatechin gallate-ion salt according to any one of claims 1 to 5, characterized in that: The preparation method comprises the following steps: The chitosan material, epigallocatechin gallate and additives are dispersed in a solvent, and an ionization salt-forming reaction is carried out, and then the supramolecular chitosan-epigallocatechin gallate-ion salt is obtained after evaporation treatment and drying treatment.

7. The method for preparing supramolecular chitosan-epigallocatechin gallate-ion salt according to claim 6, characterized in that: The time of the ionization salt-forming reaction is 1h-24h.

8. The method for preparing supramolecular chitosan-epigallocatechin gallate-ion salt according to claim 6, characterized in that: The temperature of the evaporation treatment is 30°C-100°C, and the time is 1h-4h; the temperature of the drying treatment is 30°C-100°C, and the time is 4h-48h.

9. The method for preparing supramolecular chitosan-epigallocatechin gallate-ion salt according to claim 6, characterized in that: The solvent is selected from one or more of ethanol, water, methanol, isopropanol, acetone, propylene glycol, butylene glycol, and pentanediol.

10. An application of supramolecular chitosan-epigallocatechin gallate-ion salt, characterized in that: The supramolecular chitosan-epigallocatechin gallate-ion salt described in any one of claims 1 to 5 is used to prepare antioxidant, anti-aging, antibacterial, oil-controlling, anti-inflammatory, soothing skin care products or to prepare carriers for delivering drugs.